A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

NCT06972472 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

600

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity
Overweight
Type 2 Diabetes

Interventions

DRUG: Orforglipron
DRUG: Placebo

Sponsor

Eli Lilly and Company